Research ExplorerPublicationsTherapy for Clostridium difficile infection - any news beyon...

Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin?

Standard

Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin? / Manthey, C F; Eckmann, L; Fuhrmann, V.

In: EXPERT REV CLIN PHAR, Vol. 10, No. 11, 11.2017, p. 1239-1250.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Manthey, CF, Eckmann, L & Fuhrmann, V 2017, 'Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin?', EXPERT REV CLIN PHAR, vol. 10, no. 11, pp. 1239-1250. https://doi.org/10.1080/17512433.2017.1362978

APA

Manthey, C. F., Eckmann, L., & Fuhrmann, V. (2017). Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin? EXPERT REV CLIN PHAR, 10(11), 1239-1250. https://doi.org/10.1080/17512433.2017.1362978

Vancouver

Manthey CF, Eckmann L, Fuhrmann V. Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin? EXPERT REV CLIN PHAR. 2017 Nov;10(11):1239-1250. https://doi.org/10.1080/17512433.2017.1362978

Bibtex

@article{bb9a66fe89d7443e9006629147ae841c,
title = "Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin?",
abstract = "INTRODUCTION: Infections with Clostridium difficile (CDI) represent a major burden for the health care system. Treatment is generally by antibiotic therapy with metronidazole and vancomycin, but efficacy remains suboptimal. Areas covered: This review discusses established and emerging treatment options for CDI, and current therapeutic guidelines, taking into account disease severity and risk of relapse. Expert commentary: New therapeutic approaches, including antibodies and new classes of antibiotics, and new measures for preventing infection with vaccines are under development in phase II/III clinical trials. We performed a systematic literature review using the search terms 'Clostridium difficile' and 'treatment'.",
keywords = "Animals, Anti-Bacterial Agents, Clostridium Infections, Clostridium difficile, Drug Design, Humans, Metronidazole, Practice Guidelines as Topic, Recurrence, Severity of Illness Index, Vancomycin, Journal Article, Review",
author = "Manthey, {C F} and L Eckmann and V Fuhrmann",
year = "2017",
month = nov,
doi = "10.1080/17512433.2017.1362978",
language = "English",
volume = "10",
pages = "1239--1250",
journal = "EXPERT REV CLIN PHAR",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "11",

}

RIS

TY - JOUR

T1 - Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin?

AU - Manthey, C F

AU - Eckmann, L

AU - Fuhrmann, V

PY - 2017/11

Y1 - 2017/11

N2 - INTRODUCTION: Infections with Clostridium difficile (CDI) represent a major burden for the health care system. Treatment is generally by antibiotic therapy with metronidazole and vancomycin, but efficacy remains suboptimal. Areas covered: This review discusses established and emerging treatment options for CDI, and current therapeutic guidelines, taking into account disease severity and risk of relapse. Expert commentary: New therapeutic approaches, including antibodies and new classes of antibiotics, and new measures for preventing infection with vaccines are under development in phase II/III clinical trials. We performed a systematic literature review using the search terms 'Clostridium difficile' and 'treatment'.

AB - INTRODUCTION: Infections with Clostridium difficile (CDI) represent a major burden for the health care system. Treatment is generally by antibiotic therapy with metronidazole and vancomycin, but efficacy remains suboptimal. Areas covered: This review discusses established and emerging treatment options for CDI, and current therapeutic guidelines, taking into account disease severity and risk of relapse. Expert commentary: New therapeutic approaches, including antibodies and new classes of antibiotics, and new measures for preventing infection with vaccines are under development in phase II/III clinical trials. We performed a systematic literature review using the search terms 'Clostridium difficile' and 'treatment'.

KW - Animals

KW - Anti-Bacterial Agents

KW - Clostridium Infections

KW - Clostridium difficile

KW - Drug Design

KW - Humans

KW - Metronidazole

KW - Practice Guidelines as Topic

KW - Recurrence

KW - Severity of Illness Index

KW - Vancomycin

KW - Journal Article

KW - Review

U2 - 10.1080/17512433.2017.1362978

DO - 10.1080/17512433.2017.1362978

M3 - SCORING: Review article

C2 - 28766951

VL - 10

SP - 1239

EP - 1250

JO - EXPERT REV CLIN PHAR

JF - EXPERT REV CLIN PHAR

SN - 1751-2433

IS - 11

ER -